title: Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline.
abstract: OBJECTIVE
  The aim of this single-arm, prospective, multicenter phase II trial (MiX) was to increase treatment options for women with metastatic breast cancer pretreated with anthracycline and taxane by evaluation of the efficacy and toxicity of the combination of mitomycin C and capecitabine.
  
  
  METHODS
  From 03/2004 to 06/2007, a total of 39 patients were recruited and received mitomycin C in combination with capecitabine. The primary end-point was to determinate the tumor response according to Response Evaluation Criteria in Solid Tumors and the rate of toxicities (safety). The secondary study objective was the evaluation of the time to progression (i.e. efficacy).
  
  
  RESULTS
  The median time to progression was 9.3 months (95% confidence interval=6.6-12.0 months) and the median survival was 12.8 months (95% confidence interval=6.8-18.8 months). Most treatment-related adverse events were mild to moderate.
  
  
  CONCLUSIONS
  Mitomycin C and capecitabine is a good taxane-free option in patients with metastatic breast cancer previously treated with anthracycline.
authors.affiliation: Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany.
authors.forename: Katrin
authors.initials: K
authors.lastname: Almstedt
authors.affiliation: Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Fasching
authors.affiliation: Department of Gynecology and Obstetrics, St. Marien Hospital, Amberg, Germany.
authors.forename: Anton
authors.initials: A
authors.lastname: Scharl
authors.affiliation: Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany.
authors.forename: Claudia
authors.initials: C
authors.lastname: Rauh
authors.affiliation: Department of Gynecology and Obstetrics, Ludwig Maximilian University, Munich, Germany.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Rack
authors.affiliation: Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Hein
authors.affiliation: Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany.
authors.forename: Carolin C
authors.initials: CC
authors.lastname: Hack
authors.affiliation: Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany.
authors.forename: Christian M
authors.initials: CM
authors.lastname: Bayer
authors.affiliation: Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany.
authors.forename: Sebastian M
authors.initials: SM
authors.lastname: Jud
authors.affiliation: Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany.
authors.forename: Michael G
authors.initials: MG
authors.lastname: Schrauder
authors.affiliation: Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany.
authors.forename: Matthias W
authors.initials: MW
authors.lastname: Beckmann
authors.affiliation: Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany Michael.lux@uk-erlangen.de.
authors.forename: Michael P
authors.initials: MP
authors.lastname: Lux
mesh_terms: D018943:Anthracyclines / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use*; D009362:Neoplasm Metastasis
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D016685:Mitomycin; D000069287:Capecitabine
keywords: Breast cancer; capecitabine; chemotherapy; metastasis; mitomycin C